These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18514387)

  • 21. Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation.
    Vemulakonda VM; Somogyi GT; Kiss S; Salas NA; Boone TB; Smith CP
    J Urol; 2005 Feb; 173(2):621-4. PubMed ID: 15643276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder.
    Jang J; Park EY; Seo SI; Hwang TK; Kim JC
    BJU Int; 2006 Aug; 98(2):435-9. PubMed ID: 16879691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of effects of chitosan in preventing hemorrhagic cystitis in rats induced by cyclophosphamide.
    Okamura T; Masui T; St John MK; Cohen SM; Taylor RJ
    Hinyokika Kiyo; 1995 Apr; 41(4):289-96. PubMed ID: 7785558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of COX-2 expression by acrolein in the rat model of hemorrhagic cystitis.
    Macedo FY; Baltazar F; Mourão LC; Almeida PR; Mota JM; Schmitt FC; Ribeiro RA
    Exp Toxicol Pathol; 2008 Apr; 59(6):425-30. PubMed ID: 18234483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epinephrine promotes hemostasis in rats with cyclophosphamide-induced hemorrhagic cystitis.
    Chow YC; Yang S; Huang CJ; Tzen CY; Huang PL; Su YH; Wang PS
    Urology; 2006 Mar; 67(3):636-41. PubMed ID: 16527596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Applications of Botulinum toxin in urogynaecology.
    Sinha D; Karri K; Arunkalaivanan AS
    Eur J Obstet Gynecol Reprod Biol; 2007 Jul; 133(1):4-11. PubMed ID: 17275980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?
    Chapple C; De Ridder D
    BJU Int; 2009 Nov; 104(9):1188-90. PubMed ID: 19681899
    [No Abstract]   [Full Text] [Related]  

  • 28. Editorial Comment from Dr Kitta to effect of intrathecal administration of E-series prostaglandin 1 receptor antagonist in a cyclophosphamide-induced cystitis rat model.
    Kitta T
    Int J Urol; 2013 Feb; 20(2):241. PubMed ID: 22973832
    [No Abstract]   [Full Text] [Related]  

  • 29. Cyclophosphamide induced cystitis: role of nitric oxide synthase, cyclooxygenase-1 and 2, and NK(1) receptors.
    Linares-Fernández BE; Alfieri AB
    J Urol; 2007 Apr; 177(4):1531-6. PubMed ID: 17382773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intradetrusor botulinum toxin injections for neurogenic overactive bladder: are we there yet?
    Lemack GE
    Eur Urol; 2008 Feb; 53(2):240-1. PubMed ID: 17997019
    [No Abstract]   [Full Text] [Related]  

  • 31. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.
    Karsenty G; Elzayat E; Delapparent T; St-Denis B; Lemieux MC; Corcos J
    J Urol; 2007 Mar; 177(3):1011-4. PubMed ID: 17296399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravesical botulinum type A toxin injection in patients with overactive bladder: Trigone versus trigone-sparing injection.
    Lucioni A; Rapp DE; Gong EM; Fedunok P; Bales GT
    Can J Urol; 2006 Oct; 13(5):3291-5. PubMed ID: 17076955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The current standing of intramural injection of botulinum neurotoxin in managing the overactive bladder.
    Drake MJ
    BJU Int; 2008 Jul; 102 Suppl 1():1. PubMed ID: 18665970
    [No Abstract]   [Full Text] [Related]  

  • 34. Bladder botulinum toxin A injection can benefit patients with radiation and chemical cystitis.
    Chuang YC; Kim DK; Chiang PH; Chancellor MB
    BJU Int; 2008 Sep; 102(6):704-6. PubMed ID: 18485037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
    Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
    J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection.
    Cohen BL; Rivera R; Barboglio P; Gousse A
    J Urol; 2007 Mar; 177(3):1006-10; discussion 1010. PubMed ID: 17296397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure.
    Yokoyama O; Miwa Y; Oyama N; Aoki Y; Ito H; Akino H
    J Urol; 2007 Nov; 178(5):2208-12. PubMed ID: 17870108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re: Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
    Cartwright R; Cardozo L
    J Urol; 2007 Feb; 177(2):796-7; author reply 797. PubMed ID: 17222687
    [No Abstract]   [Full Text] [Related]  

  • 39. Editorial comment.
    Greenfield SP
    Urology; 2010 Jul; 76(1):231; author reply 231. PubMed ID: 20599118
    [No Abstract]   [Full Text] [Related]  

  • 40. Editorial comment.
    Bologna R
    Urology; 2010 Jul; 76(1):231-2; author reply 232. PubMed ID: 20599119
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.